NovoCure Limited (NVCR)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.

Aggiungi a watchlist

22,01

-0,26

(-1,17%)

Alla chiusura: 04:00PM EDT

22,22

+0,21

(+0,95%)

Dopo ore:

07:01PM EDT

I prezzi di scambio non provengono da tutti i mercati

Capitalizzazione	2,369B
Beta (mensile su 5 anni)	0,49
Rapporto PE (ttm)	N/D
EPS (ttm)	-1,81
Prossima data utili	02 mag 2024
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	26,92

Tutte

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in